Sunitinib malate for the treatment of metastatic renal cell carcinoma and gastrointestinal stromal tumors.
about
Vascular endothelial growth factor inhibitors: investigational therapies for the treatment of psoriasisSafe handling of oral antineoplastic medications: focus on targeted therapeutics in the home settingMolecular Targeted Therapies of Aggressive Thyroid CancerWithdrawal of anticancer therapy in advanced disease: a systematic literature reviewTargeting RTK Signaling Pathways in CancerAssociation Study of a Functional Variant on ABCG2 Gene with Sunitinib-Induced Severe Adverse Drug ReactionGenome-wide analysis of gene expression in primate taste buds reveals links to diverse processesSunitinib Induced Immune Thrombocytopenia.Severe toxicity induced by accumulation of active sunitinib metabolite in a Japanese patient with renal cell carcinoma: a case report.Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2.Prevalence of QT prolongation and associated LVEF changes in diabetic patients over a four-year retrospective time periodComparative Analysis between Immunochemotherapy and Target Therapy for Metastatic Renal Cell Carcinoma: Overview of Treatment-Related Adverse Events and the Dropout Rate in KoreaAnti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action?Quantitation of unbound sunitinib and its metabolite N-desethyl sunitinib (SU12662) in human plasma by equilibrium dialysis and liquid chromatography-tandem mass spectrometry: application to a pharmacokinetic study.PRKX, TTBK2 and RSK4 expression causes Sunitinib resistance in kidney carcinoma- and melanoma-cell lines.Response-predictive gene expression profiling of glioma progenitor cells in vitro.Marginal increase of sunitinib exposure by grapefruit juice.Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation.Sunitinib produces neuroprotective effect via inhibiting nitric oxide overproduction.Prediction of the likelihood of drug interactions with kinase inhibitors based on in vitro and computational studies.Determination of sunitinib and its active metabolite, N-desethyl sunitinib in mouse plasma and tissues by UPLC-MS/MS: assay development and application to pharmacokinetic and tissue distribution studies.New therapies for dedifferentiated papillary thyroid cancerOral adverse events associated with tyrosine kinase and mammalian target of rapamycin inhibitors in renal cell carcinoma: a structured literature review.Suppression of phosphoinositide 3-kinase signaling and alteration of multiple ion currents in drug-induced long QT syndromeShared mechanism of teratogenicity of anti-angiogenic drugs identified in the chicken embryo model.Oral administration of sunitinib malate for long-term survival of a patient with multiple lung metastases from renal leiomyosarcoma.Endothelial follicle stimulating hormone receptor in primary kidney cancer correlates with subsequent response to sunitinib.Severe toxicity of skin rash, fever and diarrhea associated with imatinib: case report and review of skin toxicities associated with tyrosine kinase inhibitors.Pigment epithelium-derived factor as an impending therapeutic agent against vascular epithelial growth factor-driven tumor-angiogenesis.Investigational VEGF antagonists for psoriasis.Therapeutic targeting of VEGF in the treatment of glioblastoma.Current status and future prospects for anti-angiogenic therapies in cancer.Drug interactions with sunitinib.Pharmacokinetic Aspects of Vascular Endothelial Growth Factor Tyrosine Kinase Inhibitors.In Vitro and In Vivo Evaluation of Targeted Sunitinib-Loaded Polymer Microbubbles Against Proliferation of Renal Cell Carcinoma.Pharmacokinetic drug-drug interactions of tyrosine kinase inhibitors: A focus on cytochrome P450, transporters, and acid suppression therapy.Overexpression of CYP3A4 in a COLO 205 Colon Cancer Stem Cell Model in vitro.5-Hydroxy-7-azaindolin-2-one, a novel hybrid of pyridinol and sunitinib: design, synthesis and cytotoxicity against cancer cells.Guillain-Barré Syndrome following Treatment with Sunitinib Malate.Detecting functional changes with [(18)F]FAZA in a renal cell carcinoma mouse model following sunitinib therapy.
P2860
Q22305863-A36023F0-37BC-49B0-A31F-767193741095Q23923997-209A61A9-F230-41FB-AF53-C36EFE1C96BEQ26774734-D3CA3519-D24F-4DEF-BFAA-55B40ADFF2F5Q26777486-3DEB3AD7-32FE-4A05-966A-6AF5F1D925B0Q26781278-91400059-B291-4580-9690-19EC774DD5A5Q28550377-1A6556F4-5BE8-4702-948E-783C1A221E49Q28752223-68CB6D4E-83C2-409F-8F6D-F524CC560527Q33428370-421A3341-101B-453E-A5DB-03299744D09EQ33438859-EA85D441-01DC-4EFC-B36E-B7C0B43CC39AQ33710574-377047D2-A89D-49FA-9020-0BA8B8F5FD33Q33806055-5B9E7CF8-6452-4838-82DD-E01595990785Q33931392-E95E05FC-6262-41FE-89A4-039832BC9100Q34088265-038E55D5-CB80-4CB0-9D6B-AD6E5F779611Q34132880-6C48252C-A1B2-40B1-B726-3BCF281A3284Q34226634-4C83F674-164D-4798-9F44-29BBDC7FDCB3Q34277599-F6039FAE-1264-4165-80EB-3A77AF5CC219Q34594877-13534352-5D3E-49D2-BCC8-E6DDB956DB1AQ34714310-280CBB66-8E72-410E-A893-D80B60EFC408Q35083762-352C8DCC-D0BC-4979-B503-E1DC269994E7Q35115436-FA6287D0-7E4D-4601-BA77-7365C8E8DE39Q35311474-35EDF018-81D1-4B58-9ECB-D85FD304AC54Q35381593-B27F7F00-9C3A-4EBE-A9A1-F3EB8BE65066Q35705188-E24B2CB2-E3E8-4530-BAA7-3D4C4C75216BQ36387356-2748837A-1887-4C01-BF69-AB974E753563Q37117375-ADA29449-41CC-4A0C-BAD1-A6B99F39725BQ37152297-E646938F-CF43-413D-82F7-729B92C7434EQ37294895-693F64DE-52B2-498A-9D79-BFCAF6EAC532Q37385584-78367954-16A2-4D7B-924D-FE4084DA374BQ37828119-805136C9-EA51-4686-9083-9BE2A39AF188Q37956733-25D39E96-7B3F-4C84-98CD-F857EB8CACEAQ38033241-13A8586A-999D-46AC-ACFA-A1B8B42603AEQ38088366-54B793CF-4C84-4E0E-950F-194250EEB1B1Q38176853-9DEDA8BF-ADEC-4393-90CE-A524F8EA6E75Q38552109-FDB3BB36-FCC6-430A-82D3-DB8C7FECA210Q38790666-9676A10E-5EEC-41C2-AF77-B70D441027B7Q39031326-57A36417-8C86-4C64-BF05-196E51F7B99BQ39614141-E1FF6EE5-0FC6-43E1-81D1-B8EF2C53ECAFQ39794896-2EDDBD4F-F488-4E6F-91BC-C250C3F4A418Q41465130-2BC11916-3043-4F4E-B502-FD3D22E9E99FQ41505826-40D7A296-71E7-4767-BF98-AD0FEDEFEF99
P2860
Sunitinib malate for the treatment of metastatic renal cell carcinoma and gastrointestinal stromal tumors.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Sunitinib malate for the treat ...... strointestinal stromal tumors.
@en
type
label
Sunitinib malate for the treat ...... strointestinal stromal tumors.
@en
prefLabel
Sunitinib malate for the treat ...... strointestinal stromal tumors.
@en
P1476
Sunitinib malate for the treat ...... strointestinal stromal tumors.
@en
P2093
Markos Leggas
Val R Adams
P304
P356
10.1016/J.CLINTHERA.2007.07.022
P577
2007-07-01T00:00:00Z